Browse medicines, page 39 of 43

Use listed on the medicine record

ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. ONGENTYS is a catechol-O-methyltransferase (COMT) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. ( 1 )

Use listed on the medicine record

ORBACTIV is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Use listed on the medicine record

TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.1 , 2.2 ) • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an…

Use listed on the medicine record

Anxiety disorders or for the short-term relief of the symptoms of anxiety

Use listed on the medicine record

Helps prevent sunburn Temporarily protects and helps relieve peeling or flaking due to minor sunburn windburn cracked lips

Use listed on the medicine record

CYTALUX is indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung. CYTALUX is an optical imaging agent indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung. ( 1 )

Use listed on the medicine record

POSFREA is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively.

Use listed on the medicine record

The reduction in volume of new heterotopic ossification

Use listed on the medicine record

Paroxysmal nocturnal hemoglobinuria

Use listed on the medicine record

PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )

Use listed on the medicine record

Fluorescence imaging

Use listed on the medicine record

Recurrent, metastatic non-squamous NSCLC after prior chemotherapy

Use listed on the medicine record

PEMAZYRE is a kinase inhibitor indicated: for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. ( 1 , 2.1 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.

Use listed on the medicine record

Intermittent claudication on the basis of chronic occlusive arterial disease of the limbs

Use listed on the medicine record

The signs and symptoms of dry eye disease

Use listed on the medicine record

DEFINITY RT is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. DEFINITY RT is an ultrasound contrast agent indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. ( 1 )

Use listed on the medicine record

Severe nausea and vomiting

Use listed on the medicine record

​Uses ​ ​Uses treats head lice, pubic (crab) lice, and body lice

Use listed on the medicine record

Hypokalemia, with or without metabolic alkalosis

Use listed on the medicine record

The production of local anesthesia in dentistry by nerve block or infiltration techniques

Use listed on the medicine record

HOMEOPATHIC INDICATIONS: For temporary relief of symptoms related to food additives, herbicides and insecticides including muscle weakness, skin irritation, poor muscle coordination, headache, cough, occasional diarrhea, dizziness, fatigue, fever, stomach pain and vomiting.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

Use listed on the medicine record

INDICATIONS & USAGE Propylthiouracil are indicated: • in patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option • to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole

Use listed on the medicine record

Pyridoxine deficiency as seen in the following

Use listed on the medicine record

Toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination

Use listed on the medicine record

Dandruff and seborrheic dermatitis

Use listed on the medicine record

Castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

Use listed on the medicine record

temporarily protects minor cuts scrapes burns temporarily relieves pain and itching associated with minor skin irritations minor burns sunburn minor cuts scrapes insect bites rashes due to poison ivy, oak, and sumac

Use listed on the medicine record

REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. ( 1 ) the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.

Use listed on the medicine record

Spinal muscular atrophy